Novartis announced an additional strategic alliance with Science 37 to initiate up to 10 new clinical trials over the next three years. The studies will blend virtual and traditional models, with increasing degrees of decentralization towards a mostly “site-less” model. Novartis was an early investor in Science 37 and together have already initiated virtual trials for cluster headache, acne and nonalcoholic steatohepatitis (NASH).   The new Novartis decentralized trials are e...